REGEND007
Phase 1Cell therapy
REGEND007 is one of 76 biologic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Astegolimab
RochePhase 3
Tozorakimab
AstraZenecaPhase 3
Avinza
HHikma Pharmaceuticals LLC
Phase 2
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Verekitug
UUpstream Bio Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REGEND007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- RRegend Therapeutics